Semnur Pharmaceuticals, Inc. SEC filings SMNR
Semnur Pharmaceuticals, Inc. has 221 filings in SEC EDGAR's recent list, going back to Mar 1, 2022. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Jul 7, 2026 (material agreement, unregistered share sale, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | May 18, 2026 | — |
| EFFECT | Filing | Dec 29, 2025 | — |
| CORRESP | Letter to the SEC | Dec 23, 2025 | — |
| 425 | Current report | Aug 22, 2025 | — |
| NT 10-Q | Notification of late filing | Aug 14, 2025 | Jun 30, 2025 |
| EFFECT | Filing | Aug 12, 2025 | — |
| CORRESP | Letter to the SEC | Aug 11, 2025 | — |
| 425 | Current report | Aug 11, 2025 | — |
| CORRESP | Letter to the SEC | Aug 8, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 7, 2025 | — |
| 425 | Current report | Jul 28, 2025 | — |
| CORRESP | Letter to the SEC | Jul 23, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 16, 2025 | — |
| 25-NSE | Delisting notice | Jul 14, 2025 | — |
| 425 | Filing | Jul 11, 2025 | — |
| CORRESP | Letter to the SEC | Jul 2, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 26, 2025 | — |
| CORRESP | Letter to the SEC | Jun 11, 2025 | — |
| UPLOAD | Letter from the SEC | May 20, 2025 | — |
| NT 10-Q | Notification of late filing | May 15, 2025 | Mar 31, 2025 |
| 425 | Current report | May 12, 2025 | — |
| CORRESP | Letter to the SEC | Apr 21, 2025 | — |
| 425 | Current report | Apr 9, 2025 | — |
| NT 10-K | Notification of late filing | Apr 1, 2025 | Dec 31, 2023 |
| UPLOAD | Letter from the SEC | Mar 28, 2025 | — |
| CORRESP | Letter to the SEC | Mar 25, 2025 | — |
| PRER14A | Proxy statement | Mar 25, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 25, 2025 | — |
| 425 | Current report | Mar 12, 2025 | — |
| 425 | Form 8-k | Feb 11, 2025 | — |
| 425 | Form 8-k | Jan 8, 2025 | — |
| UPLOAD | Letter from the SEC | Dec 12, 2024 | — |
| 425 | Current report | Dec 11, 2024 | — |
| NT 10-Q | Notification of late filing | Nov 14, 2024 | Sep 30, 2024 |
| 425 | Current report | Nov 12, 2024 | — |
| 425 | Filing | Oct 11, 2024 | — |
| 425 | Filing | Oct 7, 2024 | — |
| 425 | Current report | Sep 12, 2024 | — |
| 425 | Current report | Sep 5, 2024 | — |
| NT 10-Q | Filing | Aug 14, 2024 | Jun 30, 2024 |
| 425 | Current report | Aug 9, 2024 | — |
| 425 | Current report | Jul 10, 2024 | — |
| NT 10-Q | Notification of late filing | May 15, 2024 | Mar 31, 2024 |
| 425 | Form 425 | Dec 29, 2023 | — |
| 425 | Current report | Dec 29, 2023 | — |
| 425 | Current report | Nov 20, 2023 | — |
| 425 | Current report | Oct 11, 2023 | — |
| DEFR14A | Proxy statement | Sep 28, 2023 | — |
| 425 | Form 425 | Aug 31, 2023 | — |
| 425 | Current report | Aug 30, 2023 | — |
| 425 | Current report | Aug 28, 2023 | — |
| NT 10-Q | Notification of late filing | Aug 14, 2023 | Jun 30, 2023 |
| 425 | Current report | Aug 4, 2023 | — |
| 425 | Current report | Aug 4, 2023 | — |
| 425 | Current report | Jul 13, 2023 | — |
| 425 | Form 425 | Apr 12, 2023 | — |
| 425 | Form 425 | Apr 12, 2023 | — |
| 425 | Form 425 | Jan 26, 2023 | — |
| NT 10-Q | Form nt 0-q | Nov 14, 2022 | Sep 30, 2022 |
| EFFECT | Filing | Apr 6, 2022 | — |
| CERT | Filing | Apr 6, 2022 | — |
| 8-A12B | Form 8a-12b | Apr 6, 2022 | — |
| CORRESP | Letter to the SEC | Apr 4, 2022 | — |
| CORRESP | Letter to the SEC | Apr 4, 2022 | — |
| UPLOAD | Letter from the SEC | Mar 10, 2022 | — |
Showing 65 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SMNR (OTC), SMNRW (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Palo Alto, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1913577
- Former names
- Denali Capital Acquisition Corp. (until Sep 23, 2025)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.